Johnson & Johnson Stocks Fall 4.7% Despite Higher Full-Year Guidance
Pharmaceutical growth and a modest forecast increase sit beside slower device sales and sharply lower reported earnings.
Pharmaceutical growth and a modest forecast increase sit beside slower device sales and sharply lower reported earnings.
What's Your Reaction?
